Group 1 - The research conducted by Professor Yu Jun's team at the Chinese University of Hong Kong demonstrates that Pien Tze Huang may be an effective drug for the prevention and treatment of non-alcoholic steatohepatitis (NASH) [1] - Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population, with a prevalence of 34% in Asian populations, and about 20% of NAFLD patients progress to NASH [2] - The study indicates that Pien Tze Huang effectively prevents the progression of NASH induced by various diets, significantly inhibiting liver damage, triglyceride accumulation, and lipid peroxidation [2] Group 2 - The incidence of fatty liver disease in China has been rising, with adult prevalence reaching 12.5% to 35.4%, indicating that one in three adults may suffer from fatty liver [3] - The research by Professor Yu Jun's team provides a new approach for the prevention and treatment of the leading liver disease in China [3] - The company has been actively exploring the secondary development of Pien Tze Huang and related products, with 11 clinical research projects and 23 pharmacological studies initiated in 2024 [3]

转自：新华财经 香港中文大学于君教授团队在《Engineering》（中国工程院院刊）发表了题为"Pien Tze Huang Protects Against Non-Alcoholic Steatohepatitis by Modulating the Gut Microbiota and Metabolites in Mice"的研究论 文，利用多种饮食小鼠模型深入探讨片仔癀在预防和治疗非酒精性脂肪性肝炎中的作用。 据了解，非酒精性脂肪肝病（NAFLD）已成为全球范围内重要的健康问题，影响了25%的世界人口， 其中在亚洲人群中的发病率更是高达34%。并且，约有20%的NAFLD患者会发展为更严重的非酒精性脂 肪性肝炎（NASH），目前尚无有效的治疗方法。 中医药因其多靶点和多途径的作用机制而受到广泛关注。其中，主要成分为三七、麝香、牛黄和蛇胆的 片仔癀作为治疗病毒性肝炎和炎症疾病的中药配方，也受到关注和研究。 此项研究评估了片仔癀在NASH防治中的作用及潜在机制，阐明了片仔癀治疗过程中非酒精性脂肪性肝 炎模型肠道微生物群和代谢产物的分布以及肠道屏障功能的改善情况。 研究人员通过对小鼠粪便样本进行宏基因组 ...